GlassScriptPhysician profile
Dominique K James
NPI 1538799325
$2,157.00
in general payments reported to CMS, 2019-2025
14 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $482 · 2023: $641 · 2024: $700 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,674.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $510.33 | 2022-2025 | |
| Ultragenyx Pharmaceutical INC. | $249.98 | 2022-2024 | Dojolvi |
| Teva Pharmaceuticals USA, INC. | $231.16 | 2023-2024 | Austedo Xr, Uzedy |
| Astrazeneca Pharmaceuticals LP | $125.68 | 2025 | Airsupra |
| Lundbeck LLC | $124.99 | 2024 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.77 | 2024 | Xifaxan |
| Lilly USA, LLC | $109.09 | 2023 | Mounjaro |
| Jazz Pharmaceuticals INC. | $107.97 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $104.32 | 2022 | |
| Gilead Sciences, INC. | $104.22 | 2023 | Epclusa |
| Alexion Pharmaceuticals, INC. | $96.86 | 2022 | |
| Novo Nordisk INC | $95.96 | 2023 | Wegovy |
| Actelion Pharmaceuticals US, INC. | $95.53 | 2023 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $89.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dominique James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.